Odgovor: |
Knjige:
- Klinička farmakologija / [glavni urednici] Igor Francetić i Dinko Vitezić. Zagreb : Medicinska naklada, 2014. - sign. 615(075.8) /KLI/
- Farmakologija / [H. P. Rang... [et al.]. Zagreb : Golden marketing-Tehnička knjiga, 200. - sign. 615(075.8) /FAR/
- Rendić, Slobodan. Metabolizam lijekova i odabranih ksenobiotika. Zagreb : Medicinska naklada, 2013. - sign. 615(075.8) /REN/ m
- Basic & clinical pharmacology / edited by Bertram G. Katzung. New York : Lange Medical Booksnational : McGraw-Hill, 2004. - sign. 615(075.8) /BAS/
Članci u časopisima:
- Radman, Ivo. Talidomid : nova paradigma antiangiogene terapije zloćudnih tumora // Medix. - 7 (2001), 39 ; str. 41-44
- Mujagić, Hamza; Chabner, Bruce A.; Mujagić, Zlata. Mechanisms of action and potential therapeutic uses of thalidomide // Croatian medical journal. - 43 (2002), 3 ; str. 274-285
- Planinc-Peraica, Ana; Ostojić Kolonić, Slobodanka; Kušec, Rajko; Minigo, Hrvoje; Borovečki, Ana; Kardum-Skelin, Ika; Šušterčić, Dunja; Jakšić, Branimir. Liječenje talidomidom bolesnika s refrakternim multiplim mijelomom (MM) i Waldenstromovom makroglobulinemijom (WM) // Liječnički vjesnik. - 125(2003), supl 3 ; 153
NCBI:
- Vargesson, N. (2015), Thalidomide-induced teratogenesis: History and mechanisms. Birth Defect Res C, 105: 140–156. doi:10.1002/bdrc.21096
- Stephens TD1, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol. 2000 Jun 15;59(12):1489-99.
ResearchGate:
- Takumi Ito, Hideki Ando, Hiroshi Handa.Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences CMLS 68(9):1569-79 · May 2011
Google Scholar:
- Thalidomide: the teratogenic drug that found a role in cancer treatment. HemOnc Today, April 10, 2009
|